Literature DB >> 412520

Interconversion of conformational isomers of light chains in the Mcg immunoglobulins.

J R Firca, K R Ely, P Kremser, F A Westholm, K J Dorrington, A B Edmundson.   

Abstract

Previous crystallographic studies in this laboratory demonstrated that immunoglobulin light chains with the same amino acid sequence can have at least two and probably three or more conformations, depending on whether the second member of an interacting pair is a light or heavy chain. If a heavy chain is not available in the assembly medium, a second light chain plays the structural role of the heavy chain in the formation of a dimer. In the present work, the lambda-type light chains were dissociated from the heavy chains of a serum IgG1 immunoglobulin from the patient Mcg and reassembled noncovalently into a dimer. The reassembly process was completed by allowing the penultimate half-cystine residues to form an interchain disulfide bond. The covalently linked dimer was compared with the Mcg urinary Bence-Jones dimer, for which an atomic model has been fitted to a 2.3-A electron density map. The assembled dimer and the native Bence-Jones protein were indistinguishable in their chromatographic and electrophoretic properties, as well as in their activity in the binding of bis(dinitrophenyl)lysine. These results indicate that the light chains can be converted into the two types of Bence-Jones conformational isomers. The procedure was also reversed: the two Bence-Jones isomers were dissociated and reassembled as the single type of isomer associating with each of two heavy chains in the IgG1 protein. The change in activity occurring when a light chain associates with a heavy chain instead of a second light chain is illustrated by the fact that the Mcg IgG1 immunoglobulin does not bind dis(dinitrophenyl)lysine in measurable amounts.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 412520     DOI: 10.1021/bi00594a022

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Formation of amyloid fibers by monomeric light chain variable domains.

Authors:  Boris Brumshtein; Shannon R Esswein; Meytal Landau; Christopher M Ryan; Julian P Whitelegge; Martin L Phillips; Duilio Cascio; Michael R Sawaya; David S Eisenberg
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

2.  Dual conformations of an immunoglobulin light-chain dimer: heterogeneity of antigen specificity and idiotope profile may result from multiple variable-domain interaction mechanisms.

Authors:  F J Stevens; C H Chang; M Schiffer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Effect of cleaving interchain disulfide bridges on the radius of gyration and maximum length of anti-poly(D-alanyl) antibodies before and after reaction with tetraalanine hapten.

Authors:  I Pilz; E Schwarz; W Durchschein; A Light; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

4.  Effect of interchain disulfide bond on hapten binding properties of light chain dimer of protein 315.

Authors:  R Zidovetski; A Licht; I Pecht
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

Review 5.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

6.  Antibody domain mutants demonstrate autonomy of the antigen binding site.

Authors:  T Simon; K Rajewsky
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

7.  Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain.

Authors:  Boris Brumshtein; Shannon R Esswein; Lukasz Salwinski; Martin L Phillips; Alan T Ly; Duilio Cascio; Michael R Sawaya; David S Eisenberg
Journal:  Elife       Date:  2015-11-18       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.